Taysha Gene Therapies, Inc. filed a Form 8-K with the SEC on August 11, 2026, reporting financial results for the quarter ended June 30, 2026, along with recent business highlights furnished as a press release.

Key Highlights

  • Filing date: August 11, 2026, covering the quarter ended June 30, 2026.
  • Registrant: Taysha Gene Therapies, Inc., a Delaware corporation headquartered at 3000 Pegasus Park Drive, Suite 1430, Dallas, Texas 75247.
  • Exchange listing: Common stock ($0.00001 par value) trades on NASDAQ:TSHA.
  • Results furnished, not filed: The financial results press release (Exhibit 99.1) is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
  • Signed by: Kamran Alam, Chief Financial Officer, on August 11, 2026.

Taysha Gene Therapies Furnishes Q2 2026 Results via 8-K

According to the filing, Taysha Gene Therapies, Inc. reported its financial results for the quarter ended June 30, 2026, on August 11, 2026. The results and recent business highlights were included in a press release attached as Exhibit 99.1 to the Current Report on Form 8-K. The filing was submitted under Item 2.02, Results of Operations and Financial Condition.

The filing notes that the information in Item 2.02, including Exhibit 99.1, "is being furnished and shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, as amended." This designation means the furnished exhibit is not subject to the liabilities of that section and is not automatically incorporated by reference into other filings unless specifically stated. The company did not indicate it is an emerging growth company.

The filing also lists Exhibit 104, the Cover Page Interactive Data File, with XBRL tags embedded within the inline XBRL document. Kamran Alam, Chief Financial Officer, signed the report on behalf of Taysha Gene Therapies, Inc. on August 11, 2026. The underlying financial figures and business highlights are contained solely in Exhibit 99.1, which was not reproduced in the body of this filing.

What Was Disclosed

Taysha Gene Therapies filed an 8-K on August 11, 2026, furnishing a press release with second-quarter 2026 financial results and business highlights. The press release is attached as Exhibit 99.1 and is not deemed "filed" under the Exchange Act.